DE122006000049I1 - Verwendung von Daptomycin - Google Patents

Verwendung von Daptomycin

Info

Publication number
DE122006000049I1
DE122006000049I1 DE1999630758 DE69930758C DE122006000049I1 DE 122006000049 I1 DE122006000049 I1 DE 122006000049I1 DE 1999630758 DE1999630758 DE 1999630758 DE 69930758 C DE69930758 C DE 69930758C DE 122006000049 I1 DE122006000049 I1 DE 122006000049I1
Authority
DE
Germany
Prior art keywords
daptomycin
administering
muscle toxicity
skeletal muscle
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE1999630758
Other languages
English (en)
Other versions
DE69930758T2 (de
DE69930758D1 (de
Inventor
B Oleson
P Tally
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cubist Pharmaceuticals LLC
Original Assignee
Cubist Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122006000049(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharmaceuticals LLC filed Critical Cubist Pharmaceuticals LLC
Publication of DE122006000049I1 publication Critical patent/DE122006000049I1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
DE1999630758 1998-09-25 1999-09-24 Verwendung von Daptomycin Pending DE122006000049I1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10182898P 1998-09-25 1998-09-25
US12575099P 1999-03-24 1999-03-24
PCT/US1999/022366 WO2000018419A2 (en) 1998-09-25 1999-09-24 Methods for administration of antibiotics

Publications (1)

Publication Number Publication Date
DE122006000049I1 true DE122006000049I1 (de) 2007-01-04

Family

ID=26798675

Family Applications (3)

Application Number Title Priority Date Filing Date
DE1999630758 Pending DE122006000049I1 (de) 1998-09-25 1999-09-24 Verwendung von Daptomycin
DE200612000049 Active DE122006000049I2 (de) 1998-09-25 1999-09-24 Verwendung von Daptomycin
DE69930758T Expired - Lifetime DE69930758T2 (de) 1998-09-25 1999-09-24 Verwendung von daptomycin

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE200612000049 Active DE122006000049I2 (de) 1998-09-25 1999-09-24 Verwendung von Daptomycin
DE69930758T Expired - Lifetime DE69930758T2 (de) 1998-09-25 1999-09-24 Verwendung von daptomycin

Country Status (26)

Country Link
US (2) US6468967B1 (de)
EP (2) EP1115417B1 (de)
JP (4) JP4184607B2 (de)
KR (2) KR20100051735A (de)
CN (2) CN1530136A (de)
AT (1) ATE322280T1 (de)
AU (1) AU764348B2 (de)
BR (1) BR9914051A (de)
CA (1) CA2344318C (de)
CY (3) CY1105556T1 (de)
DE (3) DE122006000049I1 (de)
DK (2) DK1674107T3 (de)
ES (2) ES2259845T3 (de)
HK (1) HK1040363B (de)
HU (1) HU230656B1 (de)
IS (2) IS5890A (de)
LU (1) LU91254I2 (de)
NL (1) NL300232I2 (de)
NO (1) NO20011454L (de)
NZ (1) NZ510690A (de)
PL (2) PL203689B1 (de)
PT (2) PT1115417E (de)
RU (1) RU2363489C9 (de)
SI (2) SI1115417T1 (de)
TR (1) TR200100841T2 (de)
WO (1) WO2000018419A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9914051A (pt) 1998-09-25 2001-06-19 Cubist Pharm Inc Métodos para administração de antibióticos
EP1240181A2 (de) 1999-12-15 2002-09-18 Cubist Pharmaceuticals, Inc. Daptomycin analoge und deren verwendung als antibakterielle verbindungen
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
EP1908770B2 (de) * 2000-12-18 2015-07-15 Cubist Pharmaceuticals, Inc. Verfahren zur Herstellung gereinigter Lipopeptide
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
EP1932853A1 (de) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Neue Depsipeptide und Herstellungsverfahren dafür
AU2003274927A1 (en) * 2002-08-23 2004-03-11 Genome Therapeutics Corporation Methods and reagents for preventing bacteremias
US20050277581A1 (en) * 2002-11-18 2005-12-15 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20050220862A1 (en) * 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20080051326A1 (en) * 2004-11-12 2008-02-28 Alexander Dylan C Antiinfective Lipopeptides
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070238630A1 (en) * 2006-03-29 2007-10-11 Phillips Douglas H Subcutaneous skin cleanser
EP2018864A1 (de) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmazeutische Zusammensetzung, Substrat mit einer pharmazeutischen Zusammensetzung und Verwendung einer pharmazeutischen Zusammensetzung
KR20100137439A (ko) * 2008-03-04 2010-12-30 엘란 파마 인터내셔널 리미티드 항감염제의 안정성 액체 포뮬레이션 및 항감염제의 조정된 용량투여 요법
JP5797112B2 (ja) 2008-07-17 2015-10-21 アコーダ セラピューティクス インコーポレイテッド 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
DE102008046610A1 (de) * 2008-09-09 2010-03-11 Biomet Deutschland Gmbh Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt
ES2809177T3 (es) 2008-10-07 2021-03-03 Horizon Orphan Llc Inhalación de levofloxacino para reducir la inflamación pulmonar
AU2009302478B2 (en) 2008-10-07 2015-09-03 Horizon Orphan Llc Aerosol fluoroquinolone formulations for improved pharmacokinetics
WO2010048630A1 (en) 2008-10-24 2010-04-29 Los Angeles Biomedical Reserch Institute At Harbor-Ucla Medical Center Anti-infective hydroxy-phenyl-benzoates and methods of use
AU2009330245C1 (en) 2008-12-22 2013-09-26 Merck Sharp & Dohme Corp. Novel antibacterial agents for the treatment of gram positive infections
WO2010075416A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2011008193A1 (en) * 2009-07-13 2011-01-20 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
US8450300B2 (en) * 2009-07-13 2013-05-28 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
CA2938650C (en) 2009-09-04 2018-01-09 Raptor Pharmaceuticals Inc. Use of aerosolized levofloxacin for treating cystic fibrosis
AU2010321531C1 (en) 2009-11-23 2020-10-01 Cubist Pharmaceuticals Llc Lipopeptide compositions and related methods
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
US8461188B2 (en) 2011-10-20 2013-06-11 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
CA2868553A1 (en) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole .beta.-lactamase inhibitors
AU2013316779A1 (en) * 2012-09-11 2015-04-02 Hospira Australia Pty Ltd. Daptomycin formulations and uses thereof
CN103006562B (zh) * 2013-01-21 2014-09-17 西南大学 达托霉素醇质体制剂
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
CN109310735A (zh) * 2016-05-13 2019-02-05 我希望增效剂公司 新阳离子肽spr741对抗生素活性的增效作用
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4885243A (en) 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
US4800157A (en) 1985-09-09 1989-01-24 Eli Lilly And Company Process for producing the A-21978C antibiotics
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US4874843A (en) 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
IL93618A0 (en) * 1989-03-06 1990-12-23 Lilly Co Eli Improved diluent formulation for daptomycin
FR2755857B1 (fr) * 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
FR2772272B1 (fr) 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
BR9914051A (pt) 1998-09-25 2001-06-19 Cubist Pharm Inc Métodos para administração de antibióticos
US9393093B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device

Also Published As

Publication number Publication date
PT1674107T (pt) 2016-12-07
EP1115417B1 (de) 2006-04-05
ES2603086T3 (es) 2017-02-23
EP1674107A3 (de) 2012-06-20
CY1105556T1 (el) 2010-07-28
EP1674107A2 (de) 2006-06-28
CY2006003I2 (el) 2009-11-04
TR200100841T2 (tr) 2002-01-21
SI1674107T1 (sl) 2017-01-31
WO2000018419A3 (en) 2000-07-06
ES2259845T3 (es) 2006-10-16
EP1674107B8 (de) 2017-01-25
CA2344318C (en) 2006-07-04
WO2000018419A2 (en) 2000-04-06
EP1674107A8 (de) 2006-10-04
NO20011454D0 (no) 2001-03-22
RU2363489C9 (ru) 2010-03-20
DE69930758T2 (de) 2007-04-26
EP1674107B1 (de) 2016-08-24
PL206091B1 (pl) 2010-06-30
HU230656B1 (hu) 2017-06-28
HUP0103874A3 (en) 2002-09-30
IS8807A (is) 2009-03-10
ATE322280T1 (de) 2006-04-15
JP2006335773A (ja) 2006-12-14
JP2004339238A (ja) 2004-12-02
JP2002525335A (ja) 2002-08-13
RU2363489C2 (ru) 2009-08-10
CY2006003I1 (el) 2009-11-04
NZ510690A (en) 2002-10-25
DE69930758D1 (de) 2006-05-18
PL203689B1 (pl) 2009-11-30
HK1040363B (zh) 2007-01-26
RU2004106569A (ru) 2005-08-10
DK1115417T3 (da) 2006-07-31
AU6268799A (en) 2000-04-17
PT1115417E (pt) 2006-07-31
IS5890A (is) 2001-03-14
US6468967B1 (en) 2002-10-22
CA2344318A1 (en) 2000-04-06
LU91254I2 (fr) 2006-08-28
NL300232I1 (nl) 2006-09-01
JP2003321389A (ja) 2003-11-11
CN1530136A (zh) 2004-09-22
KR20100051735A (ko) 2010-05-17
NO20011454L (no) 2001-05-25
DK1674107T3 (en) 2016-12-19
DE122006000049I2 (de) 2007-11-08
NL300232I2 (nl) 2007-01-02
HUP0103874A2 (hu) 2002-02-28
US20020142948A1 (en) 2002-10-03
SI1115417T1 (sl) 2006-08-31
KR20010075327A (ko) 2001-08-09
AU764348B2 (en) 2003-08-14
HK1040363A1 (en) 2002-06-07
US6852689B2 (en) 2005-02-08
CY1118334T1 (el) 2017-06-28
CN1348382A (zh) 2002-05-08
JP4184607B2 (ja) 2008-11-19
PL348328A1 (en) 2002-05-20
CN1150029C (zh) 2004-05-19
BR9914051A (pt) 2001-06-19
EP1115417A2 (de) 2001-07-18

Similar Documents

Publication Publication Date Title
ATE322280T1 (de) Verwendung von daptomycin
DE69432984D1 (de) Therapeutische substituierte guanidine
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
DK0583421T3 (da) Substituerede dibenzoxazepinforbindelser, lægemidler og fremgangsmåder til anvendelse
DK1201246T3 (da) Anvendelse af trombopoietin som et medikament til behandling og forebyggelse af trombocytopeni
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
HUP0000110A2 (hu) Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények
DE69626050D1 (de) Pharmazeutische zusammensetzung enthaltend interferon-gamma stimulatoren
SE9803623D0 (sv) New therapeutic application